Select your country or region
- New Zealand
- Czech Republic
- San Marino
- Costa Rica
- Dominican Republic
- El Salvador
- Trinidad and Tobago
- Hong Kong SAR
- Saudi Arabia
- South Korea
- Sri Lanka
- Taiwan, China
- Cape Verde
- São Tomé and Príncipe
Grifols Deutschland GmbH
Grifols Deutschland was established in 1997. From the German Headquarters in Frankfurt, we manage the Bioscience sales in Germany, and Diagnostic sales in Germany, Austria and Switzerland (DACH) markets.
We offer a comprehensive portfolio of products and services from the Bioscience and Diagnostic divisions. Safety and quality are our top priorities as we deliver on our mission: improving the health and well-being of people around the world.
Industry interactions with the medical profession have a profound and positive influence patient treatment and on the value of research. As primary providers of healthcare services, both healthcare professionals and healthcare organizations, offer us unique, independent insights and expert knowledge on patients' behavior and management of diseases. The capacity of gaining access to this expertise, plays a critical role in informing and guiding industry efforts to improve the quality of patient care and treatment options. And this is why, both healthcare professionals and healthcare organizations, should be fairly compensated for their contributions, as well as for the services they provide to the industry.
Industry interactions with healthcare professionals and healthcare organizations, should not only be conducted with integrity, but should also be transparent. And this is why Grifols Group fully supports, and has voluntarily adopted, the practices reflected in the new EFPIA Disclosure Code, and will continue to support any other country codes which promulgate transparency reporting.
To the above extent, Grifols Deutschland, as member of the AKG e.V. (Arzneimittel und Kooperation im Gesundheitswesen e.V.) is fully supportive of a transparent documentation of all collaborations with healthcare professionals and healthcare organizations, and has adopted the transparency guideline contained in the AKG Code of Conduct. Based on this guideline, Grifols Deutschland publishes, within a publicly available list, all its interactions with German-based healthcare professionals and healthcare organizations.
Per instructions from AKG e.V., these interactions have been split into 4 categories: (a) Research and Development; (b) Donations; (c) Sponsoring of Educational Events; and (d) Honoraria for Services. Interactions within the category "Research and Development" will be published in an aggregate format. In the other categories, interactions will be published in an individual format, in so far as permitted under German legal requirements on personal data protection.
Commitment to patients
Every day at Grifols, patients inspire our mission to advance the discovery and development of innovative protein therapies that extend and enhance lives. We continually strive to develop new and better products and services to improve our patients' health and well being. To further our mission, Grifols Deutschland GmbH actively supports patient organizations, programs and services that promote education, disease awareness, and patient advocacy efforts in order to improve the diagnosis and treatment of disease.
Do you want to know more about one of the leading healthcare companies? Here you will find all the information about Grifols and our commitment to improving the health and well-being of people around world.
This information is aimed exclusively at authorized healthcare professionals to prescribe or supply medicinal products and its correct interpretation requires specialized training.
Are you a healthcare professional?